Eric Volkman, The Motley Fool
3 min read
Not for the first time this year, Bristol Myers Squibb (NYSE: BMY) posted an impressive quarterly earnings report Thursday morning. Investors clearly found much to like in the second-quarter figures, as they greeted the news by pushing the pharmaceutical company’s stock up by almost 2.8%, easily outpacing the benchmark S&P 500 index’s 1.5% rise.
One powerful portfolio
For the period, Bristol Myers Squibb’s revenue was $12.97 billion, representing a 6% year-over-year improvement. Hotter growth could be found on the bottom line, with net income not under generally accepted accounting principles (non-GAAP, or adjusted) zooming to $4.2 billion ($2.04 per share) from the year-ago quarter’s $3 billion.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Both headline numbers were comfortably above average analyst estimates. Pundits tracking the stock had been expecting $11.71 billion on the top line and adjusted earnings per share (EPS) of $1.61.
Bristol Myers Squibb has an admirably well-performing lineup of commercialized drugs in its aptly named growth portfolio, and this lineup was the key reason those fundamentals rose. Growth’s growth, as it were, was a lofty 15% year over year to $7.6 billion. That was led by Opdivo, with sales of almost $2.5 billion worldwide in the quarter.
Future beats?
Such improvements gave Bristol Myers Squibb management the confidence to raise annual guidance. The company now forecasts total revenue for 2026 of $49 billion to $50 billion, up from the prior range of $46 billion to $47.5 billion. The adjusted EPS forecast also got a lift — it is now $6.75 to $7, up from $6.05 to $6.35.
The prognosticators collectively modeled $47.5 billion in revenue and an adjusted EPS of $6.34.
When a company beats strongly on analyst estimates that already anticipate meaningful growth, investors understandably take notice. This globe-spanning pharmaceutical still has plenty left in the tank, and what’s more, it pays a high-yield dividend. I’d definitely flag it as a solid buy candidate.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
